Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome

Marco Ladetto*, Sonia Vallet, Andreas Trojan, Maria Dell'Aquila, Luigia Monitillo, Rosalba Rosato, Loredana Santo, Daniela Drandi, Alessandra Bertola, Patrizia Falco, Federica Cavallo, Irene Ricca, Federica De Marco, Barbara Mantoan, Beata Bode-Lesniewska, Gloria Pagliano, Roberto Francese, Alberto Rocci, Monica Astolfi, Mara CompagnoSara Mariani, Laura Godio, Lydia Marino, Marina Ruggeri, Paola Omedè, Antonio Palumbo, Mario Boccadoro

*Korrespondierende:r Autor:in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

83 Zitate (Scopus)

Abstract

Cyclooxygenase 2 (COX-2) is an inflammation-associated enzyme involved in the pathogenesis of many solid tumors, but little is known about its presence and role in hematologic neoplasms. Multiple myeloma (MM) is known to involve a deregulated cytokine network with secretion of inflammatory mediators. We thus decided to investigate the involvement of COX-2 in this neoplasm. Western blotting (WB) was used to evaluate 142 bone marrow (BM) specimens, including MM and monoclonal gammopathy of undetermined significance (MGUS). Selected cases underwent further evaluation by WB on purified CD138+ cells, immunohistochemistry (IC), and real-time polymerase chain reaction (PCR) for mRNA expression. COX-2 was expressed in 11% (2 of 18) of MGUS specimens, 31% (29 of 94) of MM at diagnosis, and 47% (14 of 30) of MM with relapsed/refractory disease. COX-2 positivity was associated with a poor outcome in terms of progression-free (18 vs 36 months; P < .001) and overall survival (28 vs 52 months; P < .05). Real-time PCR showed COX-2 mRNA overexpression. IC and cell separation studies demonstrated COX-2 expression to be restricted to malignant plasma cells. This is the first report of the presence and prognostic role of COX-2 expression in MM. Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology.

OriginalspracheEnglisch
Seiten (von - bis)4784-4791
Seitenumfang8
FachzeitschriftBlood
Jahrgang105
Ausgabenummer12
DOIs
PublikationsstatusVeröffentlicht - 15 Juni 2005
Extern publiziertJa

ASJC Scopus Sachgebiete

  • Biochemie
  • Immunologie
  • Hämatologie
  • Zellbiologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren